Clinical trials: Thrombin
Sepsis, Blood Coagulation Disorders
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death.
- Conditions
- Sepsis, Blood Coagulation Disorders, Thrombin, Disseminated Intravascular Coagulation
- Trial name
- COVID-TGT (NCT04356950)
- Testing
- Thrombin generation test assay, Fibrin generation markers assays
- Where
- 4 sites in France
- Volunteers
- 175 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Targeted Temperature Management, Cardiac Arrest
The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients
This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours.
- Conditions
- Targeted Temperature Management, Cardiac Arrest, Thrombin Function, Treatment Duration
- Trial name
- ITTC (NCT06543849)
- Testing
- Target Temperature Management Treatment
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Tang Ziren
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care.
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Trial name
- kcentra (NCT03064035)
- Testing
- 4-factor prothrombin complex concentrate (4FPCC)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- HealthPartners Institute
Thrombin, Hemostatic Disorder
Thrombin in Cardiac Surgery
Coagulopathy, bleeding, and transfusion are common in cardiac surgical patients. Our collaborator has developed a novel point of care device that can be used to assess thrombin generation in real-time in cardiac surgical…
- Conditions
- Thrombin, Hemostatic Disorder, Surgical Blood Loss, Coagulation Disorder
- Trial name
- NCT04762576
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Liver Transplantation, Thrombin
Thrombin Generation in Liver Transplant Surgery
This is a prospective observational study of 100 patients undergoing liver transplantation at a single centre. Thrombin generation and kinetics will be assessed using a novel point-of-care device, and compared to conventional…
- Conditions
- Liver Transplantation, Thrombin, Hemostasis, Surgical, Blood Coagulation Disorder Due to Liver Disease
- Trial name
- NCT04762550
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Platelet Function Tests, Thrombin Generation Tests
Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Requiring Cardiopulmonary Bypass
Coagulopathy after cardiopulmonary bypass (CPB) is associated with increased morbidity and mortality. Clot formation and clot stability are important factors in coagulation and hemostasis.
- Conditions
- Platelet Function Tests, Thrombin Generation Tests, Perioperative Coagulopathy
- Trial name
- NCT02833025
- Testing
- Thrombin generation and Platelet Function Testing
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- The Hospital for Sick Children
Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)
ImproveR International (BI-001-IM)
The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting.
- Trial name
- NCT00290849
- Testing
- Bivalirudin
- Where
- Denmark
- Volunteers
- 4,000 people
- Sponsor
- Nycomed
Thrombin Inhibition
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.
- Trial name
- NCT01150812
- Testing
- AZD8165
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AstraZeneca